4021
The incidence of thrombocytopenia in MDS is reported to be as high as 40–60% in various reports and is more commonly seen in patients presenting with higher risk disease (∼80%) by International Prognostic Scoring System (IPSS) compared to Int-1 (∼50%) or low risk MDS (12%). Thrombocytopenic MDS patients are at an increased risk of bleeding and hemorrhagic complications have been reported in 3– 50% patients with fatal hemorrhage occurring in 14–20% cases. The prognostic significance of thrombocytopenia in lower risk MDS patients (low+Int-1 risk) has not been clearly defined. To determine whether thrombocytopenia in lower risk MDS patients affects survival, we performed a retrospective study of 1,402 patients diagnosed with MDS between 1987 and 2010. Of these, 687 patients were classified by IPSS as follows: 22%(151/687) were identified as having low risk, 44% (301/687) had Int-1 risk, 4% 26/387) had Int-2, and 30% (209/687) had high risk disease. The overall incidence of thrombocytopenia (platelets <100,000/ul) across all groups was 54% (373/687) with the highest incidence being in the higher risk groups (46%), followed by Int-1 (43%) and low risk (7.5%). Of the 452 lower risk patients, 41% were thrombocytopenic (187/452). Overall, 256 lower risk patients had platelets of <150,000 and these were further divided into three subgroups based on platelet counts ranging between: 1) 100–149,000/ul; 2) 50–99,000/ul; 3) less than 50,000/ul. Median overall survival (OS) was obtained for each group. Statistical significance was calculated using Kruskal-Wallis rank sum test of equality of population. Non-thrombocytopenic lower risk patients showed a statistically significant higher median OS compared to thrombocytopenic patients (3.2 vs. 1.3 yrs p < 0.0005). Median OS progressively decreased with declining platelet range (2.4, 1.6 and 1.2 years) below 150,000/ul. Patients whose platelet counts were less than 50,000/ul had survival rates that were comparable to Int -2 patients (1.2 yrs). We conclude that the presence of thrombocytopenia predicts for poor survival in lower risk MDS patients and this information may be helpful in making therapeutic decisions.
Disclosures:
No relevant conflicts of interest to declare.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.